MMRi62

Research use only, not for human use.

MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53).

MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy.MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.

Western Blot Analysis Cell Line:WT-p53 bearing MV4-11 cells; 293cells transfected with MDM2B and MDM4 Concentration:2, 2.5, 5, 10, 40, 80, 160 μM Incubation Time:24 hours Result:Increased cleaved PARP protein and activatedcaspase 3 level in wt-p53 bearing MV4-11 cells at 2 μM for 24 h.Decreased MDM2B auto ubiquitination, increased MDM4 ubiquitination at 5 μM and 10 μM for 24 h.Induced MDM2-dependent degradation of MDM4 protein at 5 μM in NALM6 cells.Cell Proliferation Assay Cell Line:Primary AML patient cells, NALM6 cells and NALM6shp53 cells Concentration:1, 10, 25, and 50 μM Incubation Time:24 hours and 72 hours Result:Induced NALM6 cells apoptosis at 24 hand induced Primary AML patient cells at 72 h.

——

——

Apoptosis

Ferroptosis

Ferroptosis

——

——

352693-80-2

396.27

C21H15Cl2N3O

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (157.72 mM; Ultrasonic (<60°C)

Oc1c(ccc2cccnc12)C(Nc1ccccn1)c1cccc(Cl)c1Cl

——

(-20℃)

With Ice Pack

≥ 2 years